Literature DB >> 34663945

PCSK9-targeted therapies: present and future approaches.

Mahmoud Al Rifai1, Christie M Ballantyne2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34663945     DOI： 10.1038/s41569-021-00634-0

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  4 in total

1.  mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor.

Authors:  Sabrina E Iskandar; Albert A Bowers
Journal:  ACS Med Chem Lett       Date:  2022-08-26       Impact factor: 4.632

Review 2.  Inflammation and atherosclerosis: signaling pathways and therapeutic intervention.

Authors:  Peng Kong; Zi-Yang Cui; Xiao-Fu Huang; Dan-Dan Zhang; Rui-Juan Guo; Mei Han
Journal:  Signal Transduct Target Ther       Date:  2022-04-22

Review 3.  PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.

Authors:  Xiaoming Jia; Mahmoud Al Rifai; Anum Saeed; Christie M Ballantyne; Salim S Virani
Journal:  Vasc Health Risk Manag       Date:  2022-07-20

Review 4.  Newer and Emerging LDL-C Lowering Agents and Implications for ASCVD Residual Risk.

Authors:  Rishi Rikhi; Michael D Shapiro
Journal:  J Clin Med       Date:  2022-08-08       Impact factor: 4.964
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.